Ainos (AIMD) 10-Q 18 Aug 16 2016 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Aug. 18, 2016
Document Information [Line Items]
Entity Registrant Name	AMARILLO BIOSCIENCES INC
Entity Central Index Key	1,014,763
Trading Symbol	amar
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		21,394,810
Document Type	10-Q
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Amendment Flag	false

Balance Sheets (Current Period

Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Assets
Cash and cash equivalents	$ 312,261	$ 21,138
Prepaid expense and other current assets	141,517	18,154
Total current assets	453,778	39,292
Patents, net	84,842	72,105
Property and equipment, net	50,174	5,798
Total assets	588,794	117,195
Liabilities and Stockholders' Deficit
Accounts payable and accrued expenses	102,809	58,550
Accrued interest - related parties	2,534	1,706
Accounts payable – related parties		144,426
Notes payable – related parties		384,555
Convertible note payable – related party	791,481
Total current liabilities	896,824	589,237
Total liabilities	896,824	589,237
Commitments and contingencies
Stockholders' deficit
Issued and outstanding shares – 0 at June 30, 2016 and December 31, 2015
Issued and outstanding shares – 21,394,810 and 20,144,810 at June 30, 2016 and December 31, 2015, respectively	213,948	201,448
Additional paid-in capital	332,505	(76,872)
Accumulated deficit	(854,483)	(596,618)
Total stockholders' deficit	(308,030)	(472,042)
Total liabilities and stockholders’ deficit	$ 588,794	$ 117,195

Balance Sheets (Current Period3

Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Preferred Stock, Par Value (in dollars per share)	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized (in shares)	10,000,000	10,000,000
Preferred Stock, Shares Issued (in shares)	0	0
Preferred Stock, Shares Outstanding (in shares)	0	0
Common Stock, Par Value (in dollars per share)	$ 0.01	$ 0.01
Common Stock, Shares Authorized (in shares)	100,000,000	100,000,000
Common Stock, Shares Issued (in shares)	21,394,810	20,144,810
Common Stock, Outstanding Shares (in shares)	21,394,810	20,144,810

Statements of Operations (Unaud

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenues:
Sales – Herbs			$ 4,400
Total revenues			4,400
Cost of revenues:
Product sales			5,100
Total cost of revenues			5,100
Gross Margin			(700)
Operating expenses:
Research and development expenses
Selling, general and administrative expenses	135,127	102,103	255,706	213,921
Total operating expenses	135,127	102,103	255,706	213,921
Operating loss	(135,127)	(102,103)	(256,406)	(213,921)
Other income (expense)
Interest expense	(1,097)	(746)	(1,459)	(1,017)
Net loss	$ (136,224)	$ (102,849)	$ (257,865)	$ (214,938)
Basic and diluted net loss per share (in dollars per share)	$ (0.01)	$ (0.01)	$ (0.01)	$ (0.01)
Weighted average shares outstanding – basic and diluted (in shares)	21,069,535	20,144,810	20,607,173	20,144,810

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Net cash provided by (used in) operating activities:	$ (325,120)	$ (207,426)
Cash flows from investing activities:
Investment in equipment	(47,686)	(7,081)
Investment in patents	(20,446)	(3,985)
Net cash used in investing activities	(68,132)	(11,066)
Cash flows from financing activities:
Proceeds from private placement offering	421,875
Proceeds from convertible note payable – related party	262,500
Net cash provided by financing activities	684,375
Net change in cash	291,123	(218,492)
Cash and cash equivalents at beginning of period	21,138	318,556
Cash and cash equivalents at end of period	312,261	100,064
Supplemental disclosure of cash flow information
Cash paid for interest
Cash paid for income taxes
Noncash transactions:
Conversion of accounts payable – related party to convertible note payable – related party	144,426
Conversion of notes payable – related party to convertible note payable – related party	$ 384,555

Note 1 - Organization and Busin

Note 1 - Organization and Business	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Organization and Business. Amarillo Biosciences, Inc. (the "Company” or “Amarillo” or “ABI”), a Texas corporation formed in 1984, is engaged in developing biologics for the treatment of human and animal diseases. The Company’s current focus is research aimed at the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon alpha that is administered in a proprietary low dose oral form. In addition to the above core technology ABI is exploring the possibility of instituting new revenue streams along with the core technology thus expanding the Company’s current focus into a diversified business portfolio .

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Basis of Accounting [Text Block]	2. Basis of presentation. The accompanying financial statements, which should be read in conjunction with the financial statements and footnotes included in the Company's Form 10-K for the year ended December 31, 2015, filed with the Securities and Exchange Commission, are unaudited, but have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2016 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2016.

Note 3 - Financial Condition

Note 3 - Financial Condition	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Financial Condition [Text Block]	3. Financial Condition. These financial statements have been prepared in accordance with United States generally accepted accounting principles, on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has not yet achieved operating income, and its operations are funded primarily from debt and equity financings. However, losses are anticipated in the ongoing development of its business and there can be no assurance that the Company will be able to achieve or maintain profitability. The continuing operations of the Company and the recoverability of the carrying value of assets is dependent upon the ability of the Company to obtain necessary financing to fund its working capital requirements, and upon future profitable operations. The accompanying financial statements do not include any adjustments relative to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty. There can be no assurance that capital will be available as necessary to meet the Company's working capital requirements or, if the capital is available, that it will be on terms acceptable to the Company. The issuances of additional equity securities by the Company may result in dilution in the equity interests of its current stockholders. Obtaining commercial loans, assuming those loans would be available, will increase the Company's liabilities and future cash commitments. If the Company is unable to obtain financing in the amounts and on terms deemed acceptable, the business and future success may be adversely affected and the Company may cease operations. These factors raise substantial doubt regarding our ability to continue as a going concern.

Note 4 - Common Stock

Note 4 - Common Stock	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	4. Common Stock. The shareholders have authorized 100,000,000 shares of voting common shares for issuance. On June 30, 2016, a total of 25,714,017 shares of common stock were either outstanding (21,394,810) or reserved for issuance upon exercise of options (8,568) or conversion of convertible debt to stock (4,310,639). On March 10, 2016, the Board of Directors approved the Company to enter into private placements for the sale of up to 5,000,000 shares of the Company’s common stock (Private Placement 2016-2) at a price of $.1875 per share (aggregate offering amount of $937,500). During the second quarter of 2016, the Company received $421,875 from four (4) individual, outside investors for the purchase of a total of 2,250,000 shares of common stock through the 2016-2 Security Offering which contemplates the sale of a maximum of 5,000,000 shares at a cost of $.1875 per share. The required SEC Form D was filed on May 6, 2016. Subsequent to the Balance Sheet date of June 30, 2016, 1,250,000 shares were issued to three of the four investors. The remaining 1,000,000 shares for the fourth investor will be issued when the executed Private Placement Memorandum documents are received.

Note 5 - Common Stock Options a

Note 5 - Common Stock Options and Warrants	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Stock Option And Warrants [Text Block]	5. Common Stock Options and Warrants. As of June 30, 2016 there were no shares reserved as unexercised warrants and 8,568 shares reserved as unexercised options. No warrants or options expired in the first six months of 2016. A summary of the Company’s stock option activity and related information for the period ended June 30, 2016 is as follows: Options Price Range Outstanding December 31, 2015 8,568 $ 0.95 Granted - - Cancelled/Expired - - Exercised - - Outstanding June 30, 2016 8,568 0.95 Exercisable June 30, 2016 8,568 $ 0.95 A summary of the Company’s stock warrant activity and related information for the period ended June 30, 2016 Warrants Price Range Outstanding December 31, 2015 - $ - Granted - - Cancelled/Expired - - Exercised - - Outstanding June 30, 2016 - - Exercisable June 30, 2016 - $ -

Note 6 - Notes Payable - Relate

Note 6 - Notes Payable - Related Party	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Notes Payable – Related Party. June 30, 2016 December 31, 2015 Note payable – related party $ - $ 234,555 Note payable – related party - 150,000 - 384,555 Less: current portion - (384,555 ) Notes payable – related party, long term $ - $ - On November 20, 2014, the Class Three Secured Claim of Yang was deemed allowed in the amount of $150,000, secured by the same assets that secured Yang’s prepetition secured claim (See Texas Financing Statement No. 13-0029795076). This claim bears interest at the Applicable Federal Rate, will be fully amortized and paid as follows: four (4) consecutive equal annual installments of combined principal and interest, beginning September 1, 2015, and continuing on the same date of each succeeding year until September 1, 2018, when the obligation is due and payable in full. The first payment was due on September 1, 2015, in the amount of $37,811 (principal and interest). To date, no payments have been made and there has been no demand for the payment. Subsequent to consummation of the Plan, The Yang Group provided $234,555 for post-reorganization financing. This is unsecured and draws interest at the short term Applicable Federal Rate. On June 30, 2016, the two debts were consolidated into one convertible promissory note. The convertible promissory note is due on demand, unsecured, bears interest at the Short-Term Applicable Federal Rate of .64% per annum, and is convertible into Amarillo Biosciences, Inc. Common Stock at a price of $.1875 per share. The amounts owed to The Yang Group after the debts were consolidated totaled $384,555 which represented all amounts then owed to The Yang Group. Those debts along with the associated liens, security interests, and accrued interest were assigned by The Yang Group to Dr. Stephen T. Chen, effective as of June 30, 2016. Subsequent to the assignment, Dr. Chen released the lien (Texas file #13-0029795076) and authorized Amarillo Biosciences, Inc. to file a UCC-3 Amendment Statement terminating the lien.

Note 7 - Convertible Note Payab

Note 7 - Convertible Note Payable - Related Party	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Convertible Debt [Text Block]	7. Convertible Notes Payable – Related Party. On July 31, 2015, two investors paid a total of $225,000 for their subscribed investment to the Yang Group for an investment in 1,200,000 shares of ABI common stock. The investors agreed to pay a premium of $0.07 per share over the original cost of the stock, which was $0.12 per share. The Company allocated $144,426 as an Accounts payable – related party to Dr. Chen for his previous advances to the Company through The Yang Group. The remaining $80,574 was recognized as “additional paid in capital” (APIC) during the year ended December 31, 2015. Shares Subscribed Purchase Price Purchase Premium Total 200,000 $ 24,071 $ 13,429 $ 37,500 1,000,000 120,355 67,145 187,500 1,200,000 $ 144,426 $ 80,574 225,000 Less: Due to Dr. Stephen Chen (144,426 ) Additional paid in capital $ 80,574 Subsequently, an offering of $1,000,000 of Convertible Notes was made with a conversion rate of $0.168 per share. The SEC Form D was filed on April 7, 2016, and the first sale was a Convertible Promissory Note for the face amount of $144,426 to Dr. Stephen Chen, who as consideration to the Company, forwent immediate collection of the $144,126 discussed above. On March 10, 2016, the Board of Directors approved the Company to enter into private placements for the sale of up to $1,000,000 in face amount of the Company’s Convertible Promissory Notes (Private Placement 2016-1), payable on demand, and convertible into the Company’s common stock at a conversion rate of $.1875 per share. During the period ended June 30, 2016, the Company received $250,000 from Dr. Stephen T. Chen for the purchase of Convertible Promissory Notes in connection with a $1,000,000 Private Placement Convertible Note Security Offering entitled Private Placement 2016-1. In addition, Dr. Chen paid $12,500 for the purchase of Convertible Promissory Notes in connection with the same offering. Both receipts of cash were aggregated and one Convertible Note in the amount of $262,500 was issued to Dr. Chen as of March 18, 2016. The Note is due on demand, bears interest at the Short-Term Applicable Federal Rate of .65% per annum, and is convertible into Amarillo Biosciences, Inc. Common Stock at a price of $.1875 per share. On June 30, 2016, a Convertible Promissory Note in the amount of $384,555 was issued to Dr. Stephen T Chen in exchange for the aggregated amounts of the two Notes Payable – Related Party described in Note 6. The Convertible Note is due on demand, unsecured, bears interest at the Short-Term Applicable Federal Rate of .64% per annum, and is convertible into Amarillo Biosciences, Inc. Common Stock at a stock price of $.1875 per share.

Note 8 - Related Party Transact

Note 8 - Related Party Transactions	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	8. Related Party Transactions. Dr. Stephen T. Chen, Chairman, CEO and President, of the Company advanced $75,000 to the Company on a periodic basis between January 18, 2016 and March 18, 2016 to be used for general operations. The $75,000 was classified on the Balance Sheet as Accounts payable – related parties and was paid back to Dr. Chen on April 4, 2016. On May 23, 2016, Amarillo Biosciences, Inc. (“ABI”), the Principal, entered into an Agency and Service Agreement with ACTS Global Healthcare, Inc. (“ACTS Global”), a Taiwan Corporation, the Agent. ABI advanced ACTS Global “Principal Funds” in the amount of NTD $3,000,000 ($92,218 USD), to be utilized and /or expended by ACTS Global solely as instructed by ABI. Additional advances may be made by ABI to ACTS Global. ACTS Global was also engaged by ABI to perform such other business services as may be requested by ABI in the agreed geographic area of Taiwan and the Peoples Republic of China. For their services, ACTS Global, will be paid by ABI, one percent (1%) of the Principal’s services expended by the Agent at the Principal’s direction. Any other services rendered by the Agent will be paid for by the Principal based on comparable and/or reasonable values of the service rendered. As of June 30, 2016, the Company has a balance of $91,718, included in Prepaid Expenses, to be utilized.

Note 9 - Subsequent Event

Note 9 - Subsequent Event	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Subsequent Events [Text Block]	9. Subsequent Event. As stated in Note 4, above, during the second quarter of 2016, the Company received $421,875 from four (4) individual, outside investors for the purchase of a total of 2,250,000 shares of common stock through the 2016-2 Security Offering. On July 11, 2016, 1,250,000 shares were issued to three of the four investors. The remaining 1,000,000 shares for the fourth investor will be issued when the executed Private Placement Memorandum documents are received.

Note 5 - Common Stock Options15

Note 5 - Common Stock Options and Warrants (Tables)	6 Months Ended
	Jun. 30, 2016
Stock Warrants [Member]
Notes Tables
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Warrants Price Range Outstanding December 31, 2015 - $ - Granted - - Cancelled/Expired - - Exercised - - Outstanding June 30, 2016 - - Exercisable June 30, 2016 - $ -
Employee Stock Option [Member]
Notes Tables
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Options Price Range Outstanding December 31, 2015 8,568 $ 0.95 Granted - - Cancelled/Expired - - Exercised - - Outstanding June 30, 2016 8,568 0.95 Exercisable June 30, 2016 8,568 $ 0.95

Note 6 - Notes Payable - Rela16

Note 6 - Notes Payable - Related Party (Tables)	6 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Related Party Transactions [Table Text Block]	June 30, 2016 December 31, 2015 Note payable – related party $ - $ 234,555 Note payable – related party - 150,000 - 384,555 Less: current portion - (384,555 ) Notes payable – related party, long term $ - $ -

Note 7 - Convertible Note Pay17

Note 7 - Convertible Note Payable - Related Party (Tables)	6 Months Ended
	Jun. 30, 2016
Notes Tables
Convertible Debt [Table Text Block]	Shares Subscribed Purchase Price Purchase Premium Total 200,000 $ 24,071 $ 13,429 $ 37,500 1,000,000 120,355 67,145 187,500 1,200,000 $ 144,426 $ 80,574 225,000 Less: Due to Dr. Stephen Chen (144,426 ) Additional paid in capital $ 80,574

Note 4 - Common Stock (Details

Note 4 - Common Stock (Details Textual)	Jul. 11, 2016shares	Mar. 10, 2016USD ($)$ / sharesshares	Jun. 30, 2016USD ($)$ / sharesshares	Jun. 30, 2016USD ($)$ / sharesshares	Jun. 30, 2015USD ($)	Dec. 31, 2015shares
Exercise of Options [Member]
Common Stock, Capital Shares Reserved for Future Issuance			8,568	8,568
Debt Convertible to Common Stock [Member]
Common Stock, Capital Shares Reserved for Future Issuance			4,310,639	4,310,639
Maximum [Member]
Shares Authorized During Period, Private Placement		5,000,000
Private Placement [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues	1,250,000
Stock Issuable Upon Receipt of Private Placement Memorandum	1,000,000
Private Placement [Member]
Shares Authorized During Period, Private Placement			2,250,000
Sale of Stock, Price Per Share | $ / shares		$ 0.1875	$ 0.1875	$ 0.1875
Proceeds from Issuance of Private Placement | $			$ 421,875
Number of Investors			4	4
Common Stock, Shares Authorized			100,000,000	100,000,000		100,000,000
Common Stock, Shares Outstanding and Reserved			25,714,017	25,714,017
Common Stock, Shares, Outstanding			21,394,810	21,394,810		20,144,810
Shares Authorized During Period, Private Placement			2,250,000
Amount of Private Placement | $		$ 937,500
Proceeds from Issuance of Private Placement | $			$ 421,875	$ 421,875

Note 5 - Common Stock Options19

Note 5 - Common Stock Options and Warrants (Details Textual) - shares	6 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Stock Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	0
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	8,568	8,568

Note 5 - Stock Option Activity

Note 5 - Stock Option Activity (Details)	6 Months Ended
	Jun. 30, 2016$ / sharesshares
Outstanding, options (in shares) | shares	8,568
Outstanding, price range (in dollars per share) | $ / shares	$ 0.95
Granted, options (in shares) | shares
Granted, price range (in dollars per share) | $ / shares
Cancelled/Expired, options (in shares) | shares
Cancelled/Expired, price range (in dollars per share) | $ / shares
Exercised, options (in shares) | shares
Exercised, price range (in dollars per share) | $ / shares
Outstanding, options (in shares) | shares	8,568
Outstanding, price range (in dollars per share) | $ / shares	$ 0.95
Exercisable March 31, 2016, options (in shares) | shares	8,568
Exercisable March 31, 2016, price range (in dollars per share) | $ / shares	$ 0.95

Note 5 - Stock Warrant Activity

Note 5 - Stock Warrant Activity (Details)	6 Months Ended
	Jun. 30, 2016$ / sharesshares
Weighted Average [Member]
Outstanding, warrants price range (in dollars per share) | $ / shares
Granted, warrants price range (in dollars per share) | $ / shares
Cancelled/Expired, warrants price range (in dollars per share) | $ / shares
Exercised, warrants price range (in dollars per share) | $ / shares
Outstanding, warrants price range (in dollars per share) | $ / shares
Exercisable, warrants price range (in dollars per share) | $ / shares
Outstanding, warrants (in shares) | shares
Granted, warrants (in shares) | shares
Cancelled/Expired, warrants (in shares) | shares
Exercised, warrants (in shares) | shares
Outstanding, warrants (in shares) | shares
Exercisable, warrants (in shares) | shares

Note 6 - Notes Payable - Rela22

Note 6 - Notes Payable - Related Party (Details Textual)	Apr. 04, 2016USD ($)	Sep. 01, 2015USD ($)	Nov. 21, 2014USD ($)	Nov. 20, 2014USD ($)	Mar. 18, 2016USD ($)	Jun. 30, 2016USD ($)$ / shares	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)$ / shares	Dec. 31, 2015USD ($)
Chief Executive Officer [Member] | Secured Debt [Member]
Notes Payable, Related Parties				$ 150,000					$ 150,000
Chief Executive Officer [Member]
Number of Installments				4
Debt Instrument, Periodic Payment		$ 37,811
Repayments of Related Party Debt	$ 75,000							$ 0
Proceeds from Related Party Debt			$ 234,555		$ 75,000
Debt Instrument, Interest Rate, Stated Percentage						0.64%		0.64%
Debt Instrument, Convertible, Conversion Price | $ / shares						$ 0.1875		$ 0.1875
Notes Payable, Convertible, Related Parties, Classified Current						$ 384,555		$ 384,555
Notes Payable, Related Parties									384,555
Proceeds from Related Party Debt						262,500
Notes Payable, Convertible, Related Parties, Classified Current						$ 791,481		$ 791,481

Note 6 - Related Party Transact

Note 6 - Related Party Transactions (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015	Nov. 20, 2014
Chief Executive Officer [Member] | Unsecured Debt [Member]
Note payable – related party		$ 234,555
Chief Executive Officer [Member] | Secured Debt [Member]
Note payable – related party		150,000	$ 150,000
Note payable – related party		384,555
Less: current portion		(384,555)
Notes payable – related party, long term	$ 0	$ 0

Note 7 - Convertible Note Pay24

Note 7 - Convertible Note Payable - Related Party (Details Textual) - USD ($)	Jul. 31, 2015	Jun. 30, 2016	Dec. 31, 2015	Apr. 07, 2016	Mar. 18, 2016	Mar. 10, 2016
Dr. Chen [Member]
Accounts Payable, Related Parties	$ 144,426		$ 144,426
Chief Executive Officer [Member] | Convertible Debt [Member]
Debt Instrument, Face Amount				$ 144,426
Chief Executive Officer [Member] | Private Placement Convertible Promissory Notes [Member] | First Issuance [Member]
Proceeds from Convertible Debt		$ 250,000
Chief Executive Officer [Member] | Private Placement Convertible Promissory Notes [Member] | Second Issuance [Member]
Proceeds from Convertible Debt		$ 12,500
Chief Executive Officer [Member] | Private Placement Convertible Promissory Notes [Member]
Debt Instrument, Face Amount					$ 262,500
Debt Instrument, Convertible, Conversion Price					$ 0.1875
Debt Instrument, Interest Rate, Stated Percentage					0.65%
Chief Executive Officer [Member]
Debt Instrument, Convertible, Conversion Price		$ 0.1875
Debt Instrument, Interest Rate, Stated Percentage		0.64%
Notes Payable, Convertible, Related Parties, Classified Current		$ 384,555
Convertible Debt [Member]
Debt Instrument, Face Amount				$ 1,000,000		$ 1,000,000
Debt Instrument, Convertible, Conversion Price				$ 0.168		$ 0.1875
Payment Received from Investors as Payment of a Subscribed Investment	$ 225,000
Common Stock, Shares Subscribed but Unissued	1,200,000		1,200,000
Premium Over the Price of Stock Price	$ 0.07
Shares Issued, Price Per Share	$ 0.12
Adjustments to Additional Paid in Capital, Stock Subscription			$ 80,574
Notes Payable, Convertible, Related Parties, Classified Current		$ 791,481

Note 7 - Convertible Notes Paya

Note 7 - Convertible Notes Payable (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Jul. 31, 2015
One of the Investors [Member]
Shares Subscribed (in shares)	200,000
Purchase Price	$ 24,071
Purchase Premium	13,429
Total	$ 37,500
Other Investors [Member]
Shares Subscribed (in shares)	1,000,000
Purchase Price	$ 120,355
Purchase Premium	67,145
Total	187,500
Dr. Chen [Member]
Due to related parties	$ (144,426)	$ (144,426)
Shares Subscribed (in shares)	1,200,000	1,200,000
Purchase Price	$ 144,426
Purchase Premium	80,574
Total	225,000
Adjustment to additional paid in capital	$ 80,574

Note 8 - Related Party Transa26

Note 8 - Related Party Transactions (Details Textual)	May 23, 2016USD ($)	May 23, 2016TWD	Apr. 04, 2016USD ($)	Nov. 21, 2014USD ($)	Mar. 18, 2016USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)
Chief Executive Officer [Member]
Repayments of Related Party Debt			$ 75,000					$ 0
Proceeds from Related Party Debt				$ 234,555	$ 75,000
ACTS Global Healthcare, Inc. [Member]
Payments for Advance to Affiliate	$ 92,218	TWD 3,000,000
Percentage to be Paid to Affiliate for Services Rendered	1.00%
Prepaid Expense, Current	$ 91,718
Proceeds from Related Party Debt						$ 262,500

Note 9 - Subsequent Event (Deta

Note 9 - Subsequent Event (Details Textual)	Jul. 11, 2016shares	Jun. 30, 2016USD ($)shares	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)
Private Placement [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues	1,250,000
Stock Issuable Upon Receipt of Private Placement Memorandum	1,000,000
Private Placement [Member]
Proceeds from Issuance of Private Placement | $		$ 421,875
Number of Investors		4	4
Shares Authorized During Period, Private Placement		2,250,000
Proceeds from Issuance of Private Placement | $		$ 421,875	$ 421,875
Shares Authorized During Period, Private Placement		2,250,000